Actively Recruiting
Study of Durvalumab With Chemoradiotherapy in Adults Aged 18 to 75 With Limited Stage Small Cell Lung Cancer
Led by Hebei Medical University Fourth Hospital · Updated on 2024-06-17
58
Participants Needed
1
Research Sites
156 weeks
Total Duration
AI-Summary
What This Trial Is About
Small cell lung cancer is a fast-growing cancer that makes up about 15% of all lung cancers. It has a very low 5-year survival rate, less than 5%, and patients without treatment typically survive only 2 to 4 months. The current standard treatment for limited stage small cell lung cancer is a combination of platinum-based chemotherapy and thoracic radiotherapy. This trial is studying the safety and effectiveness of adding durvalumab, an immune system-targeting drug, to this chemoradiotherapy approach.
CONDITIONS
Brief Title
Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)
Research Team
W
Wenbin Shen, PhD
H
Hesong Wang, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here